Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: Guidance in regimen choice for clinical trial evaluation

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1143-1147

  Drusano, G L ^a   Prichard, M ^b   Bilello, P A ^a   Bilello, J A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 77003; A 80987; ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG MIXTURE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROVIRUS INFECTION; SIMULATION; VIRUS RESISTANCE;

EID: 0030008127     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1143     Document Type: Article

References (20)

1. Belen'kii, M. S., and R. F. Schinazi. 1994. Multiple drug effect analysis with confidence intervals. Antiviral Res. 25:1-11.
2. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. The effect of 2′,3′ didehydro-3′dcoxythymidinc (D4T) in an in vitro hollow fiber pharmacodynamic model system correlates with results of dose ranging clinical studies. Antimicrob. Agents Chcmother. 38:1386-1391.
3. Bilello, J. A., P. A. Bilello, J. J. Kort, M. N. Dudley, J. Leonard, and G. L. Drusano. 1995. Efficacy of constant infusion A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro Antimicrob. Agents Chemother. 39:2523-2527.
4. 1-acid glycoprotein J Infect. Dis. 171:546-551.
5. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. Human serum α1-acid glycoprotein reduces the uptake, intracellular concentration, and antiviral activity of A 80987, an inhibitor of the human immunodeficiency virus type 1 protease Antimicrob. Agents Chemother., in press.
6. Bravo, G., R. C. Jackson, D. A. Plurad, and W. R. Greco. 1992. Comparison of theoretical and empirical mathematical models of the biochemical effects of combinations of anticancer agents. Proc. Am. Assoc Cancer Res 33:439
7. Chou, T.-C. 1991. The median effect principle and the combination index for quantitation of synergism and antagonism, p. 61-98. In T.-C. Chou and D. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press. Inc., San Diego, Calif.
8. Culberson, J. C., B. L. Bush, and V. V. Sardana, 1994. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis Methods Enzymol. 241:385-394.
9. D'Argenio, D. Z., and A. Schumitzky. 1990. ADAPT II: a program package for simulation, identification and optimal experimental design. User's manual Biomedical Simulations Resource, University of Southern California, Los Angeles.
10. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum Rctroviruses 8:153-164.
11. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5́-triphosphate with human immunodeficiency virus reverse transcriptase Proc. Natl. Acad. Sci. USA 83:8333-8337.
12. Gitterman, S. R., G. L. Drusano, M. J. Egorin, H. C. Standiford, and the VA Cooperative Studies Group. 1990. Population pharmacokinetics of zidovudine. Clin. Pharmacol. Ther. 48:161-167.
13. Kageyama, S., J. N. Weinstein, T. Shirasaka, D. J. Kempf, D. W. Norbeck, J. J. Plattner, J. Erickson, and H. Mitsuya. 1992. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 36:926-933.
14. Krown, S. E., J. Paredes, D. Bundow, B. Polsky, J. W. Gold, and N. Flomenberg. 1992. Interferon-alpha. zidovudine, and granulocyte-macrophage colony stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J. Clin. Oncol. 10:1344-1351.
15. Mayers, D. L., A. J. Japour, J.-M. Arduino, S. M. Hammer, R. Reichman, K. F. Wagner, R. Chung, J. Lane, C. S. Crumpacker, G. X. McLeod, L. A. Beckett, C. R. Roberts, D. Winslow, D. Burke, and the RV43 Study Group. 1994. Dideoxynucieoside resistance emerges with prolonged zidovudinc monotherapy Antimicrob Agents Chemother. 38:307-314.
16. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
17. 2 symmetry-based human immunodeficiency virus protease inhibitor Antimicrob. Agents Chemother. 39:1559-1564.
18. Richman, D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
19. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes. J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw and the L-697,661 Working Group. 1993. A short-term clinical evaluation of L-697.661, a non-nucleosidc inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
20. Weber, R., A. Bonetti, J. Jost, M. W. Vogt, B. Spacev, W. Siegenthaler. and R. Luthy. 1993. Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study. Infection 19:395-400.